Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4809-4815

  Ravis, William R ^a   Llanos Cuentas, Alejandro ^b   Sosa, Nestor ^c   Kreishman Deitrick, Mara ^d   Kopydlowski, Karen M ^d   Nielsen, Carl ^d   Smith, Kirsten S ^d   Smith, Philip L ^d   Ransom, Janet H ^e   Lin, Yuh Jing ^a   Grogl, Max ^f  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c Instituto Conmemorativo Gorgas de Estudios de la Salud   (Panama)

^d US Army Medical Materiel Development Activity   (United States)

^e Fast Track Drugs and Biologics   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; PAROMOMYCIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; HUMAN; ISOMER; MAXIMUM PLASMA CONCENTRATION; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN LEISHMANIASIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CHILD; FEMALE; GENTAMICINS; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; PAROMOMYCIN;

EID: 84884270884     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00628-13     Document Type: Article

References (19)

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. 2007. Cutaneous leishmaniasis. Lancet Infect. Dis. 7:581-596.
2. World Health Organization. 2010. Control of the leishmaniases. Report of a meeting of theWHOExpert Committee on the Control of Leishmaniases, Geneva, 22-26 March; WHO Technical Report Series 949. World Health Organization, Geneva, Switzerland.
3. University of Texas Southwestern Medical Center. 2008. Dermatologists identify North Texas leishmaniasis outbreak. New release Dallas: Sept. 14, 2007. University of Texas Southwestern Medical Center, Dallas, TX. http: //www.utsouthwestern.edu/utsw/cda/dept353744/files/411952.html. Accessed 15 August 2012.
4. Pehoushek JE, Quinn DM, Crum WP. 2004. Cutaneous leishmaniasis in soldiers returning from deployment to Iraq. J. Am. Acad. Dermatol. 51: S125-S128.
5. Bern C, Maguire JH, Alvar J. 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl. Trop. Dis. 2:e313. doi:10 .1371/journal.pntd.0000313.
6. Grögl M, Schuster BG, Ellis WY, Berman JD. 1999. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J. Parasitol. 85:354-359.
7. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. 1995. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35:577- 584.
8. Daneshvar H, Coombs GH, Hagan P, Phillips RS. 2003. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with attenuated lines. J. Infect. Dis. 187:1662-1668.
9. Daneshvar H, Burchmore R, Hagan P, Phillips RS. 2009. Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major. Parasitology 136:1243-1250.
10. Daneshvar H, Molaei MM, Kamiabi H, Burchmore R, Hagan P, Phillips RS. 2010. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol. 32:722-730.
11. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Hamida NB, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, MacCarthy W, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. 2013. Topical paromomycin with and without gentamicin for cutaneous leishmaniasis. N. Engl. J. Med. 368:524-532.
12. Sosa N, Capitán Z, Nieto J, Mieto M, Calzada J, Paz H, Spadafora C, Kreishman-Deitrick M, Kopydlowski K, Ullman D, McCarthy WF, Ransom JH, Berman J, Scott C, Grogl M. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am. J. Trop. Med. Hyg., in press.
13. Kanyok TP, Killian AD, Rodvold KA, Danziger LH. 1997. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob. Agents Chemother. 41:982-986.
14. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
15. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. 2004. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev. Ind. Pharm. 30:289- 296.
16. Trope GE, Lawrence JR, Hind VM, Everden A. 1979. Systemic absorption of topical and subconjunctival gentamicin. Br. J. Ophthalmol. 63: 692-693.
17. Institute for One World Health. 2010. Application for inclusion of paromomycin in the WHO Model List of Essential Medicine. Version 12 October 2006. Institute for One World Health, San Francisco, CA. http://archives.who .int/eml/expcom/expcom15/applications/newmed/paromomycin/paromomycin.pdf.
18. Roberts MS, Cross SE, Anissimov YG. 2004. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin Pharmacol. Physiol. 17:3-16.
19. Shaw JE. 1984. Pharmacokinetics of nitroglycerin and clonidine delivered by transdermal route. Am. Heart J. 108:217-222.